Macrocyclic compounds as TRK kinase inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9902741
SERIAL NO

15632187

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein ring A, ring B, W, m, D, R2, R2a, R3, R3a, and Z are as defined herein, are inhibitors of Trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ARRAY BIOPHARMA INC3200 WALNUT ST BOULDER CO 80301

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Andrews, Steven W Boulder, US 121 3409
Condroski, Kevin Ronald Boulder, US 33 822
Haas, Julia Boulder, US 83 2074
Jiang, Yutong Boulder, US 86 2396
Kolakowski, Gabrielle R Boulder, US 73 976
Seo, Jeongbeob Boulder, US 52 1260
Yang, Hong-Woon Boulder, US 15 312
Zhao, Qian Boulder, US 243 1622

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 27, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 27, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00